In vivo stable hg-197(m) compounds, method for the production thereof and use thereof in nuclear medical diagnostics and endoradionuclide therapy (theranostics)
AssigneeHelmholtz-Zentrum Dresden-Rossendorf E.V.
InventorsHans-Jürgen PIETZSCH, Martin WALTHER, Thomas WÜNSCHE
Life of this patent
Estimating the term…
Abstract
The present invention relates to in vivo stable 197(m)Hg compounds according to formula (E) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the production of the 197(m)Hg compounds comprising the step of radiolabeling of organic precursor compounds with NCA 197(m)Hg by electrophilic substitution; and the use of the 197(m)Hg compounds for nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer.
Claims17
A 197(m)Hg compound according to the following formula
- wherein:
- both 197(m)Hg-substituents Ar and Y are linked by at least one aliphatic and/or aromatic spacer molecule;
- the curved line is the aliphatic and/or aromatic spacer molecule;
- Ar is an unsubstituted or substituted -aryl or -heteroaryl group;
- and
- Y is an unsubstituted or substituted -aryl or -heteroaryl group.
An organic precursor compound according to the formula (Ebridge-prec)
- wherein both Ar and Y are linked by at least one aliphatic and/or aromatic spacer molecule, wherein Ar is an unsubstituted or substituted -aryl or -heteroaryl group, and Y is an unsubstituted or substituted -aryl or -heteroaryl group;
- M is Sn, B or Si;
- R10 is selected from H, unsubstituted or substituted C1 to C15-alkyl, -aryl or -heteroaryl groups, and
- i is 2 or 3.
Dependencies are inferred from the claim text.